EC
LENZ

EcoR1 Capital’s LENZ Therapeutics LENZ Stock Holding History

EcoR1 Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-346,772
Closed -$8.23M – 74
2024
Q3 		$8.23M Sell
346,772
-873,002
-72% -$19.4M 0.28% 44
2024
Q2 		$21.1M Hold
1,219,774
– – 0.65% 33
2024
Q1 		$27.2M Sell
1,219,774
-4
-0% -$83 0.69% 29
2023
Q4 		$22.4M Hold
1,219,778
– – 0.58% 29
2023
Q3 		$21.2M Hold
1,219,778
– – 0.71% 26
2023
Q2 		$22.2M Hold
1,219,778
– – 0.54% 27
2023
Q1 		$20.9M Buy
1,219,778
+403,764
+49% +$6.53M 0.67% 26
2022
Q4 		$19M Buy
816,014
+589,995
+261% +$13.7M 0.58% 29
2022
Q3 		$5.01M Buy
226,019
+59,993
+36% +$1.43M 0.15% 49
2022
Q2 		$3.2M Buy
166,026
+19,700
+13% +$439K 0.11% 53
2022
Q1 		$5.22M Buy
146,326
+47,912
+49% +$3M 0.16% 51
2021
Q4 		$8.56M Buy
+98,414
New +$8.15M 0.27% 41

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EcoR1 Capital's LENZ Position: Q4 2024 in Review

EcoR1 Capital sold out of LENZ Therapeutics (LENZ) in Q4 2024, closing a stake of 346,772 shares — an estimated $8.23M sold.

EcoR1 Capital first reported a position in LENZ in Q4 2021 and held it in 12 quarters. The position peaked at $27.2M in Q1 2024. 94 funds tracked by Wall St. Rank hold LENZ as of Q4 2024.

  • EcoR1 Capital reported no remaining LENZ Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EcoR1 Capital sold 346,772 LENZ Therapeutics shares in Q4 2024, an estimated $8.23M.
  • EcoR1 Capital first reported a position in LENZ Therapeutics in Q4 2021 and held it in 12 quarters.
  • EcoR1 Capital's LENZ Therapeutics position peaked at $27.2M in Q1 2024.
  • 94 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2024.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.